Neurosteroids are steroids synthesized de novo in the brain from cholesterol in an independent manner from peripheral steroid sources. The term "neuroactive steroid" includes all steroids independent of their origin, and newly synthesized analogs of neurosteroids that modify neuronal activities. In vivo application of neuroactive steroids induces potent anxiolytic, antidepressant, anticonvulsant, sedative, analgesic and amnesic effects, mainly through interaction with the γ-aminobutyric acid type-A receptor (GABAAR). However, neuroactive steroids also act as positive or negative allosteric regulators on several ligand-gated channels including N-methyl-d-aspartate receptors (NMDARs), nicotinic acetylcholine receptors (nAChRs) and ATP-gated purinergic P2X receptors. Seven different P2X subunits (P2X1-7) can assemble to form homotrimeric or heterotrimeric ion channels permeable for monovalent cations and calcium. Among them, P2X2, P2X4, and P2X7 are the most abundant within the brain and can be regulated by neurosteroids. Transmembrane domains are necessary for neurosteroid binding, however, no generic motif of amino acids can accurately predict the neurosteroid binding site for any of the ligand-gated ion channels including P2X. Here, we will review what is currently known about the modulation of rat and human P2X by neuroactive steroids and the possible structural determinants underlying neurosteroid-induced potentiation and inhibition of the P2X2 and P2X4 receptors. This article is part of the Special Issue on "Purinergic Signaling: 50 years".

Faculty of Science Charles University Prague Czech Republic

Institute of Organic Chemistry and Biochemistry Czech Academy of Sciences Prague Czech Republic

Institute of Physiology Czech Academy of Sciences Prague Czech Republic

000      

00000naa a2200000 a 4500

001      

bmc23010811

003      

CZ-PrNML

005      

20230801132632.0

007      

ta

008      

230718s2023 enk f 000 0|eng||

009      

AR

024    7_

$a 10.1016/j.neuropharm.2023.109542 $2 doi

035    __

$a (PubMed)37040816

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a enk

100    1_

$a Sivcev, Sonja $u Institute of Physiology, Czech Academy of Sciences, Prague, Czech Republic; Faculty of Science, Charles University, Prague, Czech Republic

245    10

$a Neurosteroids as positive and negative allosteric modulators of ligand-gated ion channels: P2X receptor perspective / $c S. Sivcev, E. Kudova, H. Zemkova

520    9_

$a Neurosteroids are steroids synthesized de novo in the brain from cholesterol in an independent manner from peripheral steroid sources. The term "neuroactive steroid" includes all steroids independent of their origin, and newly synthesized analogs of neurosteroids that modify neuronal activities. In vivo application of neuroactive steroids induces potent anxiolytic, antidepressant, anticonvulsant, sedative, analgesic and amnesic effects, mainly through interaction with the γ-aminobutyric acid type-A receptor (GABAAR). However, neuroactive steroids also act as positive or negative allosteric regulators on several ligand-gated channels including N-methyl-d-aspartate receptors (NMDARs), nicotinic acetylcholine receptors (nAChRs) and ATP-gated purinergic P2X receptors. Seven different P2X subunits (P2X1-7) can assemble to form homotrimeric or heterotrimeric ion channels permeable for monovalent cations and calcium. Among them, P2X2, P2X4, and P2X7 are the most abundant within the brain and can be regulated by neurosteroids. Transmembrane domains are necessary for neurosteroid binding, however, no generic motif of amino acids can accurately predict the neurosteroid binding site for any of the ligand-gated ion channels including P2X. Here, we will review what is currently known about the modulation of rat and human P2X by neuroactive steroids and the possible structural determinants underlying neurosteroid-induced potentiation and inhibition of the P2X2 and P2X4 receptors. This article is part of the Special Issue on "Purinergic Signaling: 50 years".

650    _2

$a krysa rodu Rattus $7 D051381

650    _2

$a lidé $7 D006801

650    _2

$a zvířata $7 D000818

650    12

$a iontové kanály řízené ligandy $x metabolismus $7 D058446

650    12

$a neurosteroidy $7 D000081227

650    _2

$a purinergní receptory P2X $x metabolismus $7 D058469

650    _2

$a mozek $x metabolismus $7 D001921

650    _2

$a vazebná místa $7 D001665

650    _2

$a adenosintrifosfát $x metabolismus $7 D000255

650    _2

$a purinergní receptory P2X2 $x metabolismus $7 D058476

655    _2

$a časopisecké články $7 D016428

655    _2

$a přehledy $7 D016454

655    _2

$a práce podpořená grantem $7 D013485

700    1_

$a Kudova, Eva $u Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Prague, Czech Republic

700    1_

$a Zemkova, Hana $u Institute of Physiology, Czech Academy of Sciences, Prague, Czech Republic. Electronic address: zemkova@biomed.cas.cz

773    0_

$w MED00003497 $t Neuropharmacology $x 1873-7064 $g Roč. 234, č. - (2023), s. 109542

856    41

$u https://pubmed.ncbi.nlm.nih.gov/37040816 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y p $z 0

990    __

$a 20230718 $b ABA008

991    __

$a 20230801132629 $b ABA008

999    __

$a ok $b bmc $g 1963310 $s 1197076

BAS    __

$a 3

BAS    __

$a PreBMC-MEDLINE

BMC    __

$a 2023 $b 234 $c - $d 109542 $e 20230409 $i 1873-7064 $m Neuropharmacology $n Neuropharmacology $x MED00003497

LZP    __

$a Pubmed-20230718